PharmaEssentia Corporation

TWSE:6446 Stock Report

Market Cap: NT$189.1b

PharmaEssentia Management

Management criteria checks 3/4

PharmaEssentia's CEO is Ko-Chung Lin, appointed in Jan 2017, has a tenure of 7.83 years. directly owns 1.73% of the company’s shares, worth NT$3.27B. The average tenure of the management team and the board of directors is 5.1 years and 3.3 years respectively.

Key information

Ko-Chung Lin

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenure7.8yrs
CEO ownership1.7%
Management average tenure5.1yrs
Board average tenure3.3yrs

Recent management updates

Recent updates

We Think That There Are Issues Underlying PharmaEssentia's (TWSE:6446) Earnings

Aug 20
We Think That There Are Issues Underlying PharmaEssentia's (TWSE:6446) Earnings

PharmaEssentia Corporation's (TWSE:6446) 37% Price Boost Is Out Of Tune With Revenues

Jul 02
PharmaEssentia Corporation's (TWSE:6446) 37% Price Boost Is Out Of Tune With Revenues

PharmaEssentia Corporation's (TWSE:6446) 37% Price Boost Is Out Of Tune With Revenues

Jul 02
PharmaEssentia Corporation's (TWSE:6446) 37% Price Boost Is Out Of Tune With Revenues

Is There An Opportunity With PharmaEssentia Corporation's (TWSE:6446) 25% Undervaluation?

Apr 02
Is There An Opportunity With PharmaEssentia Corporation's (TWSE:6446) 25% Undervaluation?

Downgrade: Here's How Analysts See PharmaEssentia Corporation (GTSM:6446) Performing In The Near Term

Mar 18
Downgrade: Here's How Analysts See PharmaEssentia Corporation (GTSM:6446) Performing In The Near Term

PharmaEssentia Corporation (GTSM:6446) Just Reported And Analysts Have Been Cutting Their Estimates

Mar 06
PharmaEssentia Corporation (GTSM:6446) Just Reported And Analysts Have Been Cutting Their Estimates

Things Look Grim For PharmaEssentia Corporation (GTSM:6446) After Today's Downgrade

Mar 04
Things Look Grim For PharmaEssentia Corporation (GTSM:6446) After Today's Downgrade

PharmaEssentia (GTSM:6446) Is Using Debt Safely

Feb 10
PharmaEssentia (GTSM:6446) Is Using Debt Safely

CEO Compensation Analysis

How has Ko-Chung Lin's remuneration changed compared to PharmaEssentia's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

NT$2b

Jun 30 2024n/an/a

NT$1b

Mar 31 2024n/an/a

NT$442m

Dec 31 2023n/an/a

-NT$624m

Sep 30 2023n/an/a

-NT$890m

Jun 30 2023n/an/a

-NT$1b

Mar 31 2023n/an/a

-NT$2b

Dec 31 2022n/an/a

-NT$1b

Sep 30 2022n/an/a

-NT$2b

Jun 30 2022n/an/a

-NT$2b

Mar 31 2022n/an/a

-NT$3b

Dec 31 2021NT$9mNT$9m

-NT$3b

Sep 30 2021n/an/a

-NT$3b

Jun 30 2021n/an/a

-NT$3b

Mar 31 2021n/an/a

-NT$2b

Dec 31 2020NT$9mNT$9m

-NT$2b

Sep 30 2020n/an/a

-NT$1b

Jun 30 2020n/an/a

-NT$862m

Mar 31 2020n/an/a

-NT$856m

Dec 31 2019NT$9mNT$8m

-NT$843m

Compensation vs Market: Insufficient data to establish whether Ko-Chung's total compensation is reasonable compared to companies of similar size in the TW market.

Compensation vs Earnings: Ko-Chung's compensation has been consistent with company performance over the past year.

CEO

Ko-Chung Lin

7.8yrs

Tenure

NT$9,389,000

Compensation

Mr. Ko-Chung Lin, Ph D., is the Founder and Chief Strategy Officer of PharmaEssentia Corporation and has been its Chief Executive Officer since January 01, 2017. He also serves as a Director at PharmaEssen...

Leadership Team

NamePositionTenureCompensationOwnership
Ching-Leou Teng
Chairman & Chief Pharmaceutical Officer12.2yrsNT$8.49m1.09%
NT$ 2.1b
Ko-Chung Lin
Founder7.8yrsNT$9.39m1.73%
NT$ 3.3b
Chan-Kou Hwang
Presidentno dataNT$8.49m0.61%
NT$ 1.1b
Snow Chang
Accounting Manager & Senior Manager of Finance9.1yrsno datano data
Samuel Lin
VP and Head of Business Operations & Strategy2.8yrsno datano data
Lih-Ling Lin
Chief Scientific Officer2.3yrsno data0.010%
NT$ 19.3m
Rachel Lipsitz
VP and Head of Corporate Communications & Advocacy2.8yrsno datano data
Roddy Mcilwain
Senior VP and Head of Sales & Marketing3.8yrsno datano data
Anjana Pursnani
Senior VP & Head of People2.8yrsno datano data
Albert Qin
Chief Medical Officer7.8yrsno data0.0061%
NT$ 11.5m
Narihisa Miyachi
Head of Japan Medical Affairs6.3yrsno datano data
Yen-Tung Luan
Chief Operating Officer of Taichung Plant6.3yrsno datano data

5.1yrs

Average Tenure

Experienced Management: 6446's management team is seasoned and experienced (5.1 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Ching-Leou Teng
Chairman & Chief Pharmaceutical Officer12.2yrsNT$8.49m1.09%
NT$ 2.1b
Ko-Chung Lin
Founder3.3yrsNT$9.39m1.73%
NT$ 3.3b
Chan-Kou Hwang
President9.5yrsNT$8.49m0.61%
NT$ 1.1b
Jeffrey R. Williams
Independent Directorless than a yearno datano data
Ching-Tsun Liu
Independent Directorless than a yearno data0.13%
NT$ 239.5m
Jinn-Der Chang
Independent Director10.7yrsNT$120.00k0.029%
NT$ 54.4m
Jien-Heh Tien
Independent Director6.4yrsNT$120.00k0.00060%
NT$ 1.1m
Ming-Chuan Hsieh
Independent Directorless than a yearno data0.0012%
NT$ 2.3m
Norio Komatsu
Chairperson of Japan3.5yrsno datano data
Shen Yi Li
Director3.3yrsNT$95.00k0.24%
NT$ 461.6m
HsuehFang Hsu
Directorless than a yearno datano data
ChenJung Hsiao
Directorless than a yearno datano data

3.3yrs

Average Tenure

Experienced Board: 6446's board of directors are considered experienced (3.3 years average tenure).